Nightfood Holdings Inc. (OTCQB: NGTF), doing business as TechForce Robotics, has entered a joint development, manufacturing and licensing agreement with Oncotelic Therapeutics (OTCQB: OTLC) to co-develop AI-enhanced, GMP-compliant robotic systems for pharmaceutical manufacturing and laboratory automation. The collaboration combines TechForce's robotics engineering with Oncotelic's AI-driven pharmaceutical technologies to target improved efficiency, compliance and scalability in biopharma production.
This partnership marks TechForce Robotics' expansion into regulated healthcare markets while leveraging Oncotelic CEO Dr. Vuong Trieu's experience in oncology, drug development and AI-enabled innovation. TechForce Robotics, a wholly owned subsidiary of Nightfood Holdings, is an AI-enhanced service-robotics and automation company focused on developing, deploying, and scaling autonomous robotic solutions for hospitality, foodservice, and commercial applications. Through a vertically integrated platform that combines proprietary robotics technology, real-world operating environments, and scalable manufacturing, TechForce is accelerating the adoption of automation across multiple industries.
Nightfood Holdings, Inc. is an emerging robotics company focused on deploying AI-powered automation across multiple industries. Hospitality is the company's initial sector of entry, where its Robotics-as-a-Service (RaaS) platform addresses repetitive, labor-intensive, and operationally constrained tasks. Nightfood's long-term vision is to expand into additional verticals requiring similar automation solutions, delivering scalable robotics that improve efficiency, reliability, and revenue generation.
The latest news and updates relating to NGTF are available in the company's newsroom at http://ibn.fm/NGTF. The full press release for this announcement can be viewed at https://ibn.fm/aPEgr.
This partnership represents a significant convergence of robotics and pharmaceutical manufacturing technologies, with potential implications for the entire biopharma industry. The development of GMP-compliant robotic systems could address critical challenges in pharmaceutical production, including quality control, regulatory compliance, and production scalability. As pharmaceutical companies face increasing pressure to improve manufacturing efficiency while maintaining strict quality standards, AI-enhanced robotics solutions could provide a competitive advantage for early adopters.
The collaboration between TechForce Robotics and Oncotelic Therapeutics brings together complementary expertise in robotics engineering and pharmaceutical technology development. This combination could accelerate the development of specialized automation solutions tailored to the unique requirements of pharmaceutical manufacturing environments. The partnership's focus on laboratory automation suggests potential applications in research and development settings, where precision and reproducibility are critical factors in drug discovery and development processes.
For business leaders and technology executives, this announcement signals growing opportunities at the intersection of robotics, artificial intelligence, and regulated industries. The expansion of robotics companies into healthcare and pharmaceutical markets represents a broader trend of automation technologies moving beyond traditional manufacturing and logistics applications into more complex, regulated environments. This development could influence investment decisions and strategic planning for companies operating in both the robotics and pharmaceutical sectors.
